MedTrace Logo

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01767675 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2025-08-27

No results posted yet for this study

Summary

The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic intraperitoneal chemotherapy (HIPEC), has on the patient and this type of cancer.

The goal of HIPEC is to expose any cancer left in the abdomen after surgery to high doses of chemotherapy. The chemotherapy is heated in the hope that this will make it easier for it to get into and kill the cancer cells. The drug used for HIPEC will be carboplatin, a Food and Drug Administration (FDA) approved drug for use in ovarian, fallopian tube or primary peritoneal cancer.

Conditions

Interventions

PROCEDURE

Secondary Cytoreductive Surgery

DRUG

Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

DRUG

platinum-based systemic chemotherapy postoperatively

5 cycles

DRUG

platinum-based systemic chemotherapy postoperatively

6 cycles

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Baptist Health South Florida

    collaborator OTHER

  • Hartford HealthCare

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • University of Chicago

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • Dennis Chi, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-08
Primary Completion
2025-08-26
Completion
2025-08-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01767675 on ClinicalTrials.gov